Chinese Medical Team’s Fourth-Generation CAR-T Therapy: Revealing New Hope for B-Cell Lymphoma Treatment #CART #CellDiscovery #Lymphoma #BCellLymphoma #RRLBCL #IL7 #CCL19 In recent years, China has made significant progress in medical innovation, especially in the field of Chimeric Antigen Receptor T-cell (CAR-T) therapy, dramatically changing the landscape of treatment for malignant blood cancers. Recently, a team Read More
Lymphoma
# What Types of Lymphoma Patients Are Suitable for CAR-T Treatment in China? #CART #Lymphoma #DLBCL #LBCL #MedicalTourism #FL #MCL In recent years, CAR-T cell therapy has sparked a revolution in cancer treatment worldwide, achieving remarkable results, especially in lymphoma care. As one of the global leaders in CAR-T therapy, China has attracted a large Read More
**China Leads the CAR-T Therapy Revolution, Reshaping the Treatment Landscape of Large B-Cell Lymphoma—2024 CSCO Annual Meeting** #CSCO #CSCO2024 #Lymphoma #CART #LBCL #RRLBCL #ChinaCAR-T At the 27th Annual Chinese Society of Clinical Oncology (CSCO) Conference, held in Xiamen, China, CAR-T therapy took center stage as a key focus for the treatment of large B-cell lymphoma Read More
On April 1, 2024, the US Food and Drug Administration (FDA) granted approval to Kite, a Gilead Sciences subsidiary, for Yescarta (Axicabtagene Ciloleucel), a CAR-T cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL) who are refractory to first-line chemotherapy immunotherapy or experience recurrence within 12 months of first-line chemotherapy immunotherapy.